ClinicalTrials.Veeva

Menu

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

T

Taichung Veterans General Hospital

Status

Unknown

Conditions

Glioblastoma Multiforme
Angiogenesis

Treatments

Radiation: Chemoradiation with temozolomide

Study type

Observational

Funder types

Other

Identifiers

NCT03225963
CE15180B

Details and patient eligibility

About

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Full description

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

Enrollment

60 estimated patients

Sex

All

Ages

20 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age older than 20 year old.
  • Glioblastoma patients who will receive chemoradiation treatment.

Exclusion criteria

  • None

Trial contacts and locations

1

Loading...

Central trial contact

Hui Lin Yeh, M.D.; Weir Chiang You, M.D. Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems